Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly EBIT Margin of 440356600.0% for Q4 2023, down 44034978036.0% year-over-year from N/an in Q4 2022, and down 7347277.94% quarter-over-quarter from 5993.38% in Q3 2023.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported EBIT Margin for 4 consecutive years, with 440356600.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, EBIT Margin fell 44034978036.0% year-over-year to 440356600.0%; the TTM figure through Sep 2024 stood at 2006393700.0% (down 200638752188.0% YoY), while the FY2023 annual figure was 7711.98%, up 697419.0% from the prior year.
- EBIT Margin retreated to 440356600.0% in Q4 2023 per IKT's latest filing, from 5993.38% in the prior quarter.
- Across five years, EBIT Margin topped out at 186.56% in Q1 2021 and bottomed at 440356600.0% in Q4 2023.
- Historically, EBIT Margin has averaged 27549298.5% across 4 years, with a median of 5660.72% in 2023.
- Annual changes were most pronounced in 2022 — EBIT Margin soared 25251477 bps — and 2023, when it tumbled 2000000000 bps.
- Inhibikase Therapeutics' EBIT Margin stood at 704.66% in 2020, then plunged by 36703 bps to 259334.41% in 2021, then soared by 97 bps to 6819.64% in 2022, then sank by 6457080 bps to 440356600.0% in 2023.
- Business Quant data shows IKT's EBIT Margin at 440356600.0% in Q4 2023, 5993.38% in Q3 2023, and 5328.07% in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -5,993.38% |
| Jun 30, 2023 | -5,328.07% |
| Mar 31, 2023 | -7,307.62% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -61,899.59% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.46% |
| Dec 31, 2021 | -259,334.41% |
| Sep 30, 2021 | -1,361.22% |
| Jun 30, 2021 | -192.83% |
| Mar 31, 2021 | -186.56% |
| Dec 31, 2020 | -704.66% |
| Sep 30, 2020 | -1,761.44% |
| Jun 30, 2020 | -188.50% |
| Mar 31, 2020 | -199.42% |